Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Chang Chen et al.
 
ChiCTR2000030254
RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
120/120 inconclusive
  • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Lou (FAVIPIRAVIR)
 
ChiCTR2000029544
RCTfavipiravir standard of careCOVID 19 all comerssome concern
10/10 inconclusive
  • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
NCT04310228-FAVI (Zhao)
 
ChiCTR2000030894
RCTfavipiravir tocilizumab COVID 19 all comerssome concern
-/- inconclusive
  • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

FACCT Trial
 
NCT04392973
RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive
  • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Shinkai
 
JapicCTI-205238
RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
107/49 safety concern
  • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
Solaymani-Dodaran
 
IRCT20200318046812N1
RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
193/187 inconclusive
    AVIFAVIR
     
    NCT04434248
    RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
    20/20 suggested
    • suggested 2.9-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.
    Dabbous HM
     
    NCT04349241
    RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
    50/50 inconclusive
      NCT04542694
       
      NCT04542694
      RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
      100/100 suggested
      • suggested 1.1-fold increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 12.0-fold increase in viral clearance with a moderate degree of certainty due to some concern in risk of bias
      Ruzhentsova T
       
      NCT04501783
      RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
      112/56 suggested
      • suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • inconclusive 28 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
      Udwadia
       
      CTRI/2020/05/025114
      RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
      75/75 safety concern
      • inconclusive 37 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 94 % decrease in mechanical ventilation (time to event analysis only),mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
      • statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      7 studies excluded by filtering options (3 RCT / 4 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).